Fig. 8From: The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysisThe forest plot shows the association between Evusheld administration as a prophylaxis and infection hospitalization rate of COVID-19 infections in the double-arm groupBack to article page